Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials

References

• Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974;129(3):304-9
   PubMed Web of Science ®Google Scholar
• Xu J, Qian Y, Wang S, et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 2010;28(20):3516-21
   PubMed Web of Science ®Google Scholar
• McMinn P, Stratov I, Nagarajan L, Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 2001;32(2):236-42
   PubMed Web of Science ®Google Scholar
• Chumakov M, Voroshilova M, Shindarov L, et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 1979;60(3-4):329-40
   PubMed Web of Science ®Google Scholar
• Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010;9(2):149-56
   PubMed Web of Science ®Google Scholar
• Nagy G, Takatsy S, Kukan E, et al. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 1982;71(3):217-27
   PubMed Web of Science ®Google Scholar
• Mizuta K, Abiko C, Murata T, et al. Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol 2005;43(12):6171-5
   PubMed Web of Science ®Google Scholar
• Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999;341(13):929-35
   PubMed Web of Science ®Google Scholar
• Sarma N, Sarkar A, Mukherjee A, et al. Epidemic of hand, foot and mouth disease in West Bengal, India in August, 2007: a multicentric study. Indian J Dermatol 2009;54(1):26-30
   PubMedGoogle Scholar
• Kim KH. Enterovirus 71 infection: an experience in Korea, 2009. Korean J Pediatr 2010;53(5):616-22
   PubMedGoogle Scholar
• Chan LG, Parashar UD, Lye MS, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 2000;31(3):678-83
   PubMed Web of Science ®Google Scholar
• Tan X, Huang X, Zhu S, et al. The persistent circulation of enterovirus 71 in People’s Republic of China: causing emerging nationwide epidemics since. 2008;PLoS One 2011;6(9):e25662
   Google Scholar
• Tu PV, Thao NT, Perera D, et al. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis 2007;13(11):1733-41
   PubMed Web of Science ®Google Scholar
• Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010;10(11):778-90
   PubMed Web of Science ®Google Scholar
• Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol 2007;17(6):371-9
   PubMed Web of Science ®Google Scholar
• Pallansch MA, Oberste MS. Enterovirus 71 encephalitis: a new vaccine on the horizon? Lancet 2013;381(9871):976-7
   PubMed Web of Science ®Google Scholar
• WHO. A Guide to clinical management and public health response for hand, foot and mouth disease (HFMD). 2011. Available from: www.wpro.who.int/publications/docs/GuidancefortheclinicalmanagementofHFMD.pdf
   Google Scholar
• Chang LY, King CC, Hsu KH, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 2002;109(6):e88
   PubMed Web of Science ®Google Scholar
• Wang SM, Ho TS, Lin HC, et al. Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity. Eur J Clin Microbiol Infect Dis 2012;31(6):1219-24
   PubMed Web of Science ®Google Scholar
• Diedrich S, Weinbrecht A, Schreier E. Seroprevalence and molecular epidemiology of enterovirus 71 in Germany. Arch Virol 2009;154(7):1139-42
   PubMed Web of Science ®Google Scholar
• Zhu FC, Liang ZL, Meng FY, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS One 2012;7(5):e37206
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zhu S, Guo X, et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol J 2010;7:300
   PubMed Web of Science ®Google Scholar
• Ooi EE, Phoon MC, Ishak B, Chan SH. Seroepidemiology of human enterovirus 71, Singapore. Emerg Infect Dis 2002;8(9):995-7
   PubMed Web of Science ®Google Scholar
• Wong S, Yip C, Lau S, Yuen K. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol Infect 2010;138(08):1071-89
   PubMedGoogle Scholar
• Ang LW, Koh BK, Chan KP, et al. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore 2009;38(2):106-12
   PubMed Web of Science ®Google Scholar
• Huang ML, Chiang PS, Chia MY, et al. Cross-reactive neutralizing antibody responses to enterovirus 71 infections in young children: implications for vaccine development. PLoS Negl Trop Dis 2013;7(2):e2067
   PubMed Web of Science ®Google Scholar
• Bible JM, Iturriza-Gomara M, Megson B, et al. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol 2008;46(10):3192-200
   PubMed Web of Science ®Google Scholar
• Brown BA, Oberste MS, Alexander JP Jr, et al. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 1999;73(12):9969-75
   PubMed Web of Science ®Google Scholar
• Oberste MS, Maher K, Kilpatrick DR, Pallansch MA. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol 1999;73(3):1941-8
   PubMed Web of Science ®Google Scholar
• Huang SW, Hsu YW, Smith DJ, et al. Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol 2009;47(11):3653-62
   PubMed Web of Science ®Google Scholar
• Wang JR, Tuan YC, Tsai HP, et al. Change of major genotype of enterovirus 71 in outbreaks of hand-foot-and-mouth disease in Taiwan between 1998 and 2000. J Clin Microbiol 2002;40(1):10-15
   PubMed Web of Science ®Google Scholar
• AbuBakar S, Chee HY, Al-Kobaisi MF, et al. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res 1999;61(1):1-9
   PubMed Web of Science ®Google Scholar
• Podin Y, Gias EL, Ong F, et al. Sentinel surveillance for human enterovirus 71 in Sarawak, Malaysia: lessons from the first 7 years. BMC Public Health 2006;6:180
   PubMed Web of Science ®Google Scholar
• Huang SW, Kiang D, Smith DJ, Wang JR. Evolution of re-emergent virus and its impact on enterovirus 71 epidemics. Exp Biol Med (Maywood) 2011;236(8):899-908
   PubMed Web of Science ®Google Scholar
• Tee KK, Lam TT, Chan YF, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 2010;84(7):3339-50
   PubMed Web of Science ®Google Scholar
• Mizuta K, Aoki Y, Suto A, et al. Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 2009;27(24):3153-8
   PubMed Web of Science ®Google Scholar
• Kung SH, Wang SF, Huang CW, et al. Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998-2005. Clin Microbiol Infect 2007;13(8):782-7
   PubMed Web of Science ®Google Scholar
• Arita M, Nagata N, Iwata N, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 2007;81(17):9386-95
   PubMed Web of Science ®Google Scholar
• Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008;26(15):1855-62
   PubMed Web of Science ®Google Scholar
• Dong C, Liu L, Zhao H, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 2011;29(37):6269-75
   PubMed Web of Science ®Google Scholar
• Dong C, Wang J, Liu L, et al. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum Vaccin 2010;6(12):1028-37
   PubMed Web of Science ®Google Scholar
• Wu CN, Lin YC, Fann C, et al. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001;20(5-6):895-904
   PubMed Web of Science ®Google Scholar
• Bek EJ, Hussain KM, Phuektes P, et al. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011;29(29-30):4829-38
   PubMed Web of Science ®Google Scholar
• Chiu CH, Chu C, He CC, Lin TY. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 2006;8(7):1671-8
   PubMed Web of Science ®Google Scholar
• Chung CY, Chen CY, Lin SY, et al. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 2010;28(43):6951-7
   PubMed Web of Science ®Google Scholar
• Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 2007;9(11):1299-306
   PubMed Web of Science ®Google Scholar
• Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 2007;5:6
   PubMedGoogle Scholar
• Wu TC, Wang YF, Lee YP, et al. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 2007;81(19):10310-15
   PubMed Web of Science ®Google Scholar
• Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 2010;84(1):661-5
   PubMed Web of Science ®Google Scholar
• Mao Q, Li N, Yu X, et al. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol 2012;157(1):37-41
   PubMed Web of Science ®Google Scholar
• Zhao M, Bai Y, Liu W, et al. Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses. BMC Microbiol 2013;13:287
   PubMed Web of Science ®Google Scholar
• Chou AH, Liu CC, Chang CP, et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One 2012;7(4):e34834
   PubMed Web of Science ®Google Scholar
• Hwa SH, Lee YA, Brewoo JN, et al. Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine. PLoS Negl Trop Dis 2013;7(11):e2538
   PubMed Web of Science ®Google Scholar
• Liang Z, Mao Q, Gao Q, et al. Establishing China’s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011;29(52):9668-74
   PubMed Web of Science ®Google Scholar
• Mao Q, Dong C, Li X, et al. Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice. PLoS One 2012;7(9):e46043
   PubMed Web of Science ®Google Scholar
• Huang ML, Ho MS, Lee MS. Enterovirus 71 vaccine: when will it be available? J Formos Med Assoc 2011;110(7):425-7
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang Y, Wang J, et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013;8(1):e54451
   PubMed Web of Science ®Google Scholar
• Liu JN, Wang W, Duo JY, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010;28(46):7444-51
   PubMed Web of Science ®Google Scholar
• Liang ZL, Mao QY, Wang YP, et al. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother 2013;9(8):1701-5
   PubMed Web of Science ®Google Scholar
• Zhu FC, Wang JZ, Li XL, et al. Reactogenicity and Immunogenicity of an Enterovirus 71 Vaccine in Chinese Healthy Children and Infants. Pediatr Infect Dis J 2012;31(11):1158-65
   PubMed Web of Science ®Google Scholar
• Meng FY, Li JX, Li XL, et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother 2012;8(5):668-74
   PubMed Web of Science ®Google Scholar
• Cheng A, Fung CP, Liu CC, et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013;31(20):2471-6
   PubMed Web of Science ®Google Scholar
• Zhu FC, Liang ZL, Li XL, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013;381(9871):1037-45
   PubMed Web of Science ®Google Scholar
• Li YP, Liang ZL, Xia JL, et al. Immunogenicity, Safety, and Immune Persistence of a Novel Inactivated Human Enterovirus 71 Vaccine: a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. J Infect Dis 2013;209(1):46-55
   PubMed Web of Science ®Google Scholar
• Wang LC, Kao CM, Ling P, et al. CD4 T-cell-independent antibody response reduces enterovirus 71 lethality in mice by decreasing tissue viral loads. Clin Dev Immunol 2012;2012:580696
   PubMedGoogle Scholar
• Kolpe AB, Kiener TK, Grotenbreg GM, Kwang J. Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice. Virus Res 2012;168(1-2):64-72
   PubMed Web of Science ®Google Scholar
• Hendriksen C, Arciniega JL, Bruckner L, et al. The consistency approach for the quality control of vaccines. Biologicals 2008;36(1):73-7
   PubMed Web of Science ®Google Scholar
• Hu YM, Wang X, Wang JZ, et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol 2013;20(12):1805-11
   PubMed Web of Science ®Google Scholar
• Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013;381(9882):2024-32
   PubMed Web of Science ®Google Scholar
• Chang JY, Chang CP, Tsai HH, et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 2012;30(4):703-11
   PubMed Web of Science ®Google Scholar
• Chou AH, Liu CC, Chang JY, et al. Formalin-Inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013;8(11):e79783
   PubMed Web of Science ®Google Scholar
• Mao Q, Cheng T, Zhu F, et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy Chinese infants and children. PLoS One 2013;8(11):e79599
   PubMed Web of Science ®Google Scholar
• Zhu F, Xu W, Xia J, et al. Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China. N Engl J Med 2014;370(9):818-28
   PubMed Web of Science ®Google Scholar
• Lee MS, Tseng FC, Wang JR, et al. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012;6(8):e1737
   PubMed Web of Science ®Google Scholar
• McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002;26(1):91-107
   PubMed Web of Science ®Google Scholar
• Li JX, Meng FY, Liang ZL, et al. How to understand the efficacy measurements for enterovirus type 71 vaccine? Human Vaccin Immunother 2013;10(3)
   Google Scholar
• Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011;377(9767):751-9
   PubMed Web of Science ®Google Scholar
• Wang SY, Li JX, Liang ZL, et al. A booster dose of an inactivated enterovirus 71 vaccine in Chinese young children: a randomized, double-blind, placebo-controlled clinical trial. J Infect Dis ( Accepted)
   Google Scholar
• Chia MY, Chiang PS, Chung WY, et al. Epidemiology of Enterovirus 71 Infections in Taiwan. Pediatr Neonatol 2013;pii:S1875-9572
   Google Scholar
• Chen X, Zhang Q, Li J, et al. Analysis of recombination and natural selection in human enterovirus 71. Virology 2010;398(2):251-61
   PubMed Web of Science ®Google Scholar
• Yip CC, Lau SK, Zhou B, et al. Emergence of enterovirus 71 “double-recombinant” strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Arch Virol 2010;155(9):1413-24
   PubMed Web of Science ®Google Scholar
• Chen Y, Li C, He D, et al. Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine 2013;31(2):425-30
   PubMed Web of Science ®Google Scholar
• Chang LY, Lin TY, Huang YC, et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 1999;18(12):1092-6
   PubMed Web of Science ®Google Scholar